Abstract
The neurotrophic actions of pituitary adenylate cyclase-activating polypeptide (PACAP)-38 and leukemia inhibitory factor (LIF) were investigated in human neuroblastoma SH-SY5Y cells. Effects on differentiation were assessed through monitoring morphological changes and Western blot analysis of the expression of neuronal marker proteins. In contrast to PACAP-38, which induced a 5.5-fold increase in the number of neurite-bearing cells, LIF had no significant effect on cell morphology compared to control cells over the 4-day time course. Cells co-treated with PACAP-38+LIF showed a similar increase in neurite-bearing cells compared to those treated with PACAP-38 alone. Cell morphology was similar for PACAP-38-treated and PACAP-38+LIF-co-treated cells, with the formation of bipolar neuron-like cells with long thin neurites, topped by growth cone-like structures and varicosities. SH-SY5Y cells express tyrosine hydroxylase (TH) but only low levels of the neuronal marker proteins: Bcl-2, GAP-43 and choline acetyltransferase (ChAT). Treatment of cells with PACAP-38 induced the expression of Bcl-2, GAP-43, and ChAT but did not appear to alter the expression of TH. LIF failed to induce the expression of GAP-43 and had little effect on the expression of TH, but did induce the expression of Bcl-2 and upregulated the expression of ChAT. Co-treatment with LIF had no effect on PACAP-38-induced expression of Bcl-2, GAP-43, and ChAT. Cells differentiated for 4 days with PACAP-38 or treated with LIF also displayed increased resistance to hypoxic conditions and to treatment with H2O2 and TNFα. The increased resistance to hypoxic conditions for PACAP-differentiated cells was blocked by the p38 MAP kinase inhibitor, SB203580, but not by the MEK1 inhibitor, PD98059. Additionally, cell proliferation assays show that LIF, but not PACAP-38, stimulates proliferation of SH-SY5Y cells, and this observed increase by LIF is not attenuated by co-treatment with PACAP. Further investigation of the intracellular signaling pathways mediating the neurotrophic effects of PACAP on SH-SY5Y cells indicate that neither phospholipase C activation nor Ca2+/calmodulin-dependent kinase II (CAMKII) are involved.
Similar content being viewed by others
Abbreviations
- PACAP:
-
pituitary adenylate cyclase-activating polypeptide
- VIP:
-
vasoactive intestinal peptide
- LIF:
-
leukemia inhibitory factor
- PAC1 :
-
PACAP receptor type I
- VPAC1 :
-
VIP/PACAP receptor type I
- VPAC2 :
-
VIP/PACAP receptor type 2
- GPCR:
-
G protein-coupled receptor
- AC:
-
adenylate cyclase
- Epac:
-
exchange protein directly activated by cAMP
- PKA:
-
cAMP-dependent protein kinase A
- ERK:
-
extracellular signal-regulated kinase
- PLC:
-
phospholipase C
- InsP:
-
inositol phosphates
- RA:
-
retinoic acid
- CaMKII:
-
Ca2+/calmodulin-dependent protein kinase II
- GAP-43:
-
growth-associated protein-43
- ChAT:
-
choline acetyltransferase
- TH:
-
tyrosine hydroxylase
- STAT:
-
signal transducer and activator of transcription
- PKB/Akt:
-
protein kinase B
- PI3-K:
-
phosphatidylinositol-3-kinase
- GAPDH:
-
glyceraldehyde-3-phosphate dehydrogenase
- NGF:
-
nerve growth factor
- BDNF:
-
brain-derived neurotrophic factor
- LPS:
-
lipopolysaccharide
- AIP:
-
autocamtide-2-related inhibitory peptide
- ES:
-
embryonic stem cell
- FBS:
-
fetal bovine serum
- RT-PCR:
-
reverse transcriptase polymerase chain reaction
References
Arimura, A., Somogyvari-Vigh, A., Weill, C., Fiore, R. C., Tatsuno, I., Bay, V., et al. (1994). PACAP functions as a neurotrophic factor. Annals of the New York Academy of Sciences, 739, 228–243.
Bamber, B. A., Masters, B. A., Hoyle, G. W., Brinster, R. L., & Palmiter, R. D. (1994). Leukemia inhibitory factor induces neurotransmitter switching in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 91, 7839–7843.
Banner, L. R., & Patterson, P. H. (1994). Major changes in the expression of the mRNAs for cholinergic differentiation factor/leukemia inhibitory factor and its receptor after injury to adult peripheral nerves and ganglia. Proceedings of the National Academy of Sciences of the United States of America, 91, 7109–7113.
Bilecki, W., Zapart, G., Ligeza, A., Wawrzczak-Bargiela, A., Urbanski, M. J., & Przewlocki, R. (2005). Regulation of the extracellular signal-regulated kinases following acute and chronic opioid treatment. Cellular and Molecular Life Sciences, 62, 2369–2375.
Brenneman, D. E. (2007). Neuroprotection: A comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Peptides, 28, 1720–1726.
Cazillis, M., Gonzalez, B. J., Billardon, C., Lombet, A., Fraichard, A., Samarut, J., et al. (2004). VIP and PACAP induce selective neuronal differentiation of mouse embryonic stem cells. European Journal of Neuroscience, 19, 798–808.
Chen, Y., Samal, B., Hamelink, C. R., Xiang, C. C., Chen, Y., Chen, M., et al. (2006). Neuroprotection by endogenous and exogenous PACAP following stroke. Regulatory Peptides, 137, 4–19.
Dahéron, L., Opitz, S. L., Zaehres, H., Lensch, W. M., Andrews, P. W., Itskovitz-Eldor, J., et al. (2004). LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells, 22, 770–778.
Dejda, A., Sokolowska, P., & Nowak, J. Z. (2005). Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacological Reports, 57, 307–320.
Delgado, M., Leceta, J., & Ganea, D. (2003). Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. Journal of Leukocyte Biology, 73, 155–164.
Deutsch, P. J., & Sun, Y. (1992). The 38-amino acid form of pituitary adenylate cyclase-activating polypeptide stimulates dual signaling cascades in PC12 cells and promotes neurite outgrowth. Journal of Biological Chemistry, 267, 5108–5113.
Dickson, D. W., Lee, S. C., Mattiace, L. A., Yen, S. H., & Brosnan, C. (1993). Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia, 7, 75–83.
Dohi, K., Mizushima, H., Nakajo, S., Ohtaki, H., Matsunaga, S., Aruga, T., et al. (2002). Pituitary adenylate cyclase-activating polypeptide (PACAP) prevents hippocampal neurons from apoptosis by inhibiting JNK/SAPK and p38 signal transduction pathways. Regulatory Peptides, 109, 83–88.
Encinas, M., Iglesias, M., Liu, Y., Wang, H., Muhaisen, A., Ceña, V., et al. (2000). Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. Journal of Neurochemistry, 75, 991–1003.
Falluel-Morel, A., Chafai, M., Vaudry, D., Basille, M., Cazillis, M., Aubert, N., et al. (2007). The neuropeptide pituitary adenylate cyclase-activating polypeptide exerts anti-apoptotic and differentiating effects during neurogenesis: Focus on cerebellar granule neurones and embryonic stem cells. Journal of Neuroendocrinology, 19, 321–327.
Galli, R., Pagano, S. F., Gritti, A., & Vescovi, A. L. (2000). Regulation of neuronal differentiation in human CNS stem cell progeny by leukemia inhibitory factor. Developmental Neuroscience, 22, 86–95.
Haas, C. A., Hofmann, H. D., & Kirsch, M. (1999). Expression of CNTF/LIF-receptor components and activation of STAT3 signaling in axotomized facial motoneurons: Evidence for a sequential postlesional function of the cytokines. Journal of Neurobiology, 41, 559–571.
Harmar, A. J. (2001). Family-B G-protein-coupled receptorsGenome Biology.2, 3013.3011–3013.3010.
Hart, A. M., Wiberg, M., & Terenghi, G. (2003). Exogenous leukaemia inhibitory factor enhances nerve regeneration after late secondary repair using a bioartificial nerve conduit. British Journal of Plastic Surgery, 56, 444–450.
Holtmann, B., Wiese, S., Samsam, M., Grohmann, K., Pennica, D., Martini, R., et al. (2005). Triple knock-out of CNTF, LIF, and CT-1 defines cooperative and distinct roles of these neurotrophic factors for motoneuron maintenance and function. Journal of Neuroscience, 25, 1778–1787.
Ishida, A., Kameshita, I., Okuno, S., Kitani, T., & Fujisawa, H. (1995). A novel highly specific and potent inhibitor of calmodulin-dependent protein kinase II. Biochemical and Biophysical Research Communications, 212, 806–812.
Kaur, N., Wohlhueter, A. L., & Halvorsen, S. W. (2002). Activation and inactivation of signal transducers and activators of transcription by ciliary neurotrophic factor in neuroblastoma cells. Cellular Signalling, 14, 419–429.
Konat, G. W., Kielian, T., & Marriott, I. (2006). The role of Toll-like receptors in CNS response to microbial challenge. Journal of Neurochemistry, 99, 1–12.
Langer, I., Perret, J., Verrtongen, P., Waelbroeck, M., & Robberecht, P. (2001). Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMP in CHO cells expressing Galpha16. Cell Calcium, 30, 229–234.
Lazarovici, P., Jiang, H., & Fink Jr., D. (1998). The 38-amino-acid form of pituitary adenylate cyclase-activating polypeptide induces neurite outgrowth in PC12 cells that is dependent on protein kinase C and extracellular signal-regulated kinase but not on protein kinase A, nerve growth factor receptor tyrosine kinase, p21ras G protein, and pp60c-src cytoplasmic tyrosine kinase. Molecular Pharmacology, 54, 547–558.
Li, M., David, C., Kikuta, T., Somogyvari-Vigh, A., & Arimura, A. (2005). Signaling cascades involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide-38. Journal of Molecular Neuroscience, 27, 91–105.
Lutz, E. M., Ronaldson, E., Shaw, P., Johnson, M. S., Holland, P. J., & Mitchell, R. (2006). Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: Consequences for signaling by VIP and PACAP. Molecular and Cellular Neurosciences, 31, 193–201.
MacKenzie, C. J., Lutz, E. M., Johnson, M. S., Robertson, D. N., Holland, P. J., & Mitchell, R. (2001). Mechanisms of phospholipase C activation by the vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide type 2 receptor. Endocrinology, 142, 1209–1217.
Martinou, J. C., Martinou, I., & Kato, A. C. (1992). Cholinergic differentiation factor (CDF/LIF) promotes survival of isolated rat embryonic motoneurons in vitro. Neuron, 8, 737–744.
McCulloch, D., Lutz, E. M., Johnson, M. S., Robertson, D. N., MacKenzie, C. J., Holland, P. J., et al. (2001). ADP-ribosylation factor-dependent phospholipase D activation by VPAC receptors and a PAC(1) receptor splice variant. Molecular Pharmacology, 59, 1523–1532.
McCulloch, D. A., MacKenzie, C. J., Johnson, M. S., Robertson, D. N., Holland, P. J., Ronaldson, E., et al. (2002). Additional signals from VPAC/PAC family receptors. Biochemical Society Transactions, 30, 441–446.
Michikawa, M., Kikuchi, S., & Kim, S. U. (1992). Leukemia inhibitory factor (LIF) mediated increase of choline acetyltransferase activity in mouse spinal cord neurons in culture. Neuroscience Letters, 140, 75–77.
Mitchell, R., Robertson, D. N., Holland, P. J., Collins, D., Lutz, E. M., & Johnson, M. S. (2003). ADP-ribosylation factor-dependent phospholipase D activation by the M3 muscarinic receptor. Journal of Biological Chemistry, 278, 33818–33830.
Monaghan, T. K., MacKenzie, C. J., Plevin, R., & Lutz, E. M. (2008). PACAP-38 induces neuronal differentiation of human SH-SY5Y neuroblastoma cells via cAMP-mediated activation of ERK and p38 MAP kinases. Journal of Neurochemistry, 104, 74–88.
Morooka, T., & Nishida, E. (1998). Requirement of p38 mitogen-activated protein kinase for neuronal differentiation in PC12 cells. Journal of Biological Chemistry, 273, 24285–24288.
Murphy, M., Dutton, R., Koblar, S., Cheema, S., & Bartlett, P. (1997). Cytokines which signal through the LIF receptor and their actions in the nervous system. Progress in Neurobiology, 52, 355–378.
Ng, Y. P., He, W., & Ip, N. Y. (2003). Leukemia inhibitory factor receptor signaling negatively modulates nerve growth factor-induced neurite outgrowth in PC12 cells and sympathetic neurons. Journal of Biological Chemistry, 278, 38731–38739.
Nielsen, K. M., Chaverra, M., Hapner, S. J., Nelson, B. R., Todd, V., Zigmond, R. E., et al. (2004). PACAP promotes sensory neuron differentiation: Blockade by neurotrophic factors. Molecular and Cellular Neurosciences, 25, 629–641.
Ohtaki, H., Nakamachi, T., Dohi, K., Aizawa, Y., Takaki, A., Hodoyama, K., et al. (2006). Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proceedings of the National Academy of Sciences of the United States of America, 103, 7488–7493.
Okamoto, S., Kraine, D., Sherman, K., & Lipton, S. A. (2000). Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proceedings of the National Academy of Sciences of the United States of America, 97, 7561–7566.
Okita, K., & Yamanaka, S. (2006). Intracellular signaling pathways regulating pluripotency of embryonic stem cells. Current Stem Cell Research Therapy, 1, 103–111.
Pachernik, J., Bryja, V., Esner, M., Hampl, A., & Dvorak, P. (2005). Retinoic acid-induced neural differentiation of P19 embryonal carcinoma cells is potentiated by leukemia inhibitory factor. Physiological Reviews, 54, 257–262.
Pisegna, J. R., & Wank, S. A. (1996). Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Journal of Biological Chemistry, 271, 17267–17274.
Påhlman, S., Hoehner, J. C., Nanberg, E., Hedborg, F., Fagerstrom, S., Gestblom, C., et al. (1995). Differentiation and survival influences of growth factors in human neuroblastoma. European Journal of Cancer, 31A, 453–458.
Påhlman, S., Ruusala, A.-I., Abrahamsson, L., Mattsson, M. E. K., & Esscher, T. (1984). Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbol ester-induced differentiation. Cell Differentiation, 14, 135–144.
Qiu, L., Bernd, P., & Fukada, K. (1994). Cholinergic neuronal differentiation factor (CDF)/leukemia inhibitory factor (LIF) binds to specific regions of the developing nervous system in vivo. Developments in Biologicals, 163, 516–520.
Russo, V. C., Metaxas, S., Kobayashi, K., Harris, M., & Werther, G. A. (2004). Antiapoptotic effects of leptin in human neuroblastoma cells. Endocrinology, 145, 4103–4112.
Sheward, W. J., Lutz, E. M., Copp, A. J., & Harmar, A. J. (1998). Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo. Developmental Brain Research, 109, 245–253.
Smith, A. G., Heath, J. K., Donaldson, D. D., Wong, G. G., Moreau, J., Stahl, M., et al. (1988). Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature, 336, 688–690.
Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P. H., et al. (1993). Differential signal transduction by 5 splice variants of the PACAP receptor. Nature, 365, 170–175.
Stumm, R., Kolodziej, A., Prinz, V., Endres, M., Wu, D.-F., & Höllt, V. (2007). Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage. Journal of Neurochemistry, 103, 1666–1681.
Suzuki, S., Yamashita, T., Tanaka, K., Hattori, H., Sawamoto, K., Okano, H., et al. (2005). Activation of cytokine signaling through leukemia inhibitory factor receptor (LIFR)/gp130 attenuates ischemic brain injury in rats. Journal of Cerebral Blood Flow and Metabolism, 25, 685–693.
Takeda, K., & Ichijo, H. (2002). Neuronal p38 MAPK signalling: An emerging regulator of cell fate and function in the nervous system. Genes Cells, 7, 1099–1111.
Takeda, K., Matsuzawa, A., Nishitoh, H., Tobiume, K., Kishida, S., Ninomiya-Tsuji, J., et al. (2004). Involvement of ASK1 in Ca2+-induced p38 MAP kinase activation. EMBO Reports, 5, 161–166.
Takei, N., Torres, E., Yuhara, A., Jongsma, H., Otto, C., Korhonen, L., et al. (2000). Pituitary adenylate cyclase-activating polypeptide promotes the survival of basal forebrain cholinergic neurons in vitro and in vivo: Comparison with effects of nerve growth factor. European Journal of Neuroscience, 12, 2273–2280.
Tamas, A., Reglodi, D., Szanto, Z., Borsiczky, B., Nemeth, J., & Lengvari, I. (2002). Comparative neuroprotective effects of preischemic PACAP and VIP administration in permanent occlusion of the middle cerebral artery in rats. Neuro Endocrinology Letters, 23, 249–254.
Terenghi, G. (1999). Peripheral nerve regeneration and neurotrophic factors. Journal of Anatomy, 194, 1–14.
Turnley, A. M., & Bartlett, P. F. (2000). Cytokines that signal through the leukemia inhibitory factor receptor-b complex in the nervous system. Journal of Neurochemistry, 74, 889–899.
Vaudry, D., Gonzalez, B. J., Basille, M., Yon, L., Fournier, A., & Vaudry, H. (2000). Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions. Pharmacological Reviews, 52, 269–324.
Vaudry, D., Pamantung, T. F., Basille, M., Rouselle, C., Fournier, A., Vaudry, H., et al. (2002). PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. European Journal of Neuroscience, 15, 1451–1460.
Vitalis, E. A., Costantin, J. L., Tsai, P. S., Sakakibara, H., Paruthiyil, S., Iiri, T., et al. (2000). Role of the cAMP signaling pathway in the regulation of gonadotropin-releasing hormone secretion in GT1 cells. Proceedings of the National Academy of Sciences of the United States of America, 97, 1861–1866.
Wang, G., Qi, C., Fan, G. H., Zhou, H. Y., & Chen, S. D. (2005). PACAP protects neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial complex I inhibitor, rotenone. FEBS Letters, 579, 4005–4011.
Waschek, J. A. (2002). Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. Developmental Neuroscience, 24, 14–23.
Waschek, J. A., Casillas, R. A., Nguyen, T. B., DiCicco-Bloom, E. M., Carpenter, E. M., & Rodriguez, W. I. (1998). Neural tube expression of pituitary adenylate cyclase-activating peptide (PACAP) and receptor: Potential role in patterning and neurogenesis. Proceedings of the National Academy of Sciences of the United States of America, 95, 9602–9607.
Williams, R. L., Hilton, D. J., Pease, S., Willson, T. A., Stewart, C. L., Gearing, D. P., et al. (1988). Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature, 336, 684–687.
Wolf, N., & Krieglstein, K. (1995). Phenotypic development of neonatal rat chromaffin cells in response to adrenal growth factors and glucocorticoids: Focus on pituitary adenylate cyclase activating polypeptide. Neuroscience Letters, 200, 207–210.
Yuhara, A., Ishii, K., Nishio, C., Abiru, Y., Yamada, M., Nawa, H., et al. (2003). PACAP and NGF cooperatively enhance choline acetyltransferase activity in postnatal basal forebrain neurons by complementary induction of its different mRNA species. Biochemical and Biophysical Research Communications, 301, 344–349.
Zhang, Y.-Z., Hannibal, J., Zhao, Q., Moller, K., Danielsen, N., Fahrenkrug, J., et al. (1996). Pituitary adenylate cyclase activating peptide expression in the rat dorsal root ganglia: Up-regulation after peripheral nerve injury. Neuroscience, 74, 1099–1110.
Zhang, Q., Shi, T.-J., Ji, R.-R., Zhang, Y.-T., Sundler, F., Hannibal, J., et al. (1995). Expression of pituitary adenylate cyclase-activating polypeptide in dorsal root ganglia following axotomy: time course and coexistence. Brain Research, 705, 149–158.
Zhou, C. J., Shioda, S., Shibanuma, M., Nakajo, S., Funahashi, H., Nakai, Y., et al. (1999). Pituitary adenylate cyclase-activating polypeptide receptors during development: Expression in the rat embryo at primitive streak stage. Neuroscience, 93, 375–391.
Acknowledgments
We wish to thank Dr Clett Erridge for the gifts of TNFα and LPS and Mr. Alex McDowall for the use of his anaerobic chamber. We also would like to acknowledge the influential work of Professor Akira Arimura on this research, particularly his discovery and characterization of PACAP as well as his inspiration, encouragement, and generosity to others that have led towards a much greater understanding of its biological functions. This research was supported by the Wellcome Trust.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Monaghan, T.K., Pou, C., MacKenzie, C.J. et al. Neurotrophic Actions of PACAP-38 and LIF on Human Neuroblastoma SH-SY5Y Cells. J Mol Neurosci 36, 45–56 (2008). https://doi.org/10.1007/s12031-008-9082-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-008-9082-6